New pill targets hard-to-treat lung cancer mutations
NCT ID NCT06043817
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 22 times
Summary
This study tests a new oral drug, STX-721, in people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if it can shrink tumors. About 251 participants will take the pill daily, and the study will monitor side effects and cancer response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHA Bundang Medical Center, CHA University
RECRUITINGSeongnam-si, 13496, South Korea
-
Charité - Universitätsmedizin Berlin (CBF) - Hindenburgdamm 30
RECRUITINGBerlin, 12203, Germany
-
Chungbuk National University Hospital
RECRUITINGCheongju-si, 28644, South Korea
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
City of Hope
RECRUITINGHuntington Beach, California, 92648, United States
-
City of Hope
RECRUITINGIrvine, California, 92618, United States
-
EDOG Institut de Cancerologie de l'Ouest - PPDS
RECRUITINGSaint-Herblain, Loire-Atlantique, 44115, France
-
Gustave Roussy
RECRUITINGVillejuif, 94800, France
-
Hospital Regional Universitario de Malaga - Hospital General
RECRUITINGMálaga, Malaga, 29010, Spain
-
Hospital Universitario Ramon y Cajal
RECRUITINGMadrid, 28034, Spain
-
Hospital Universitario Virgen del Rocio
RECRUITINGSeville, 41013, Spain
-
Institut Claudius Regaud - PPDS
RECRUITINGToulouse, 31059, France
-
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
RECRUITINGBarcelona, 8035, Spain
-
Levine Cancer Institute - Charlotte
RECRUITINGCharlotte, North Carolina, 28204-2990, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031-2171, United States
-
National Taiwan University Hospital
RECRUITINGTaipei, 10002, Taiwan
-
Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
RECRUITINGAmsterdam, 1066, Netherlands
-
SCRI Oncology Partners - PPDS
RECRUITINGNashville, Tennessee, 37203, United States
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 11217, Taiwan
-
Thomas Jefferson University Research Facility
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4009, United States
-
University of Utah - Huntsman Cancer Institute - PPDS
RECRUITINGSalt Lake City, Utah, 84112-5550, United States
-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
RECRUITINGDresden, 01307, Germany
Conditions
Explore the condition pages connected to this study.